News | November 06, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Silica is a proven and highly effective anti-caking agent that has been used for decades
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
